Tagworks lands $65M for its take on Nobel-winning click chemistry in bid to expand ADC, radiopharma potential
A Dutch-American biotech is out with $65 million in Series A funding to get into the clinic with what it calls an expanded scope of the popular antibody-drug conjugates class after a decade of legwork iterating on the original click chemistry findings that led to last year’s Nobel Prize.
Tagworks Pharmaceuticals, founded within the corporate labs of Philips Healthcare and spun out in 2011, has spent the past 10-plus years working with academics to get to a point where it can create so-called click-to-release reactions. Its efforts build on the work out of Joseph Fox’s lab at the University of Delaware and that of Carolyn Bertozzi, who is one of three professors to receive the Nobel Prize in Chemistry last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
